Sanara MedTech stock: FTC extends merger review. Sanara MedTech stock faces a 30-day wait.

Published on 10/24/2026 at 03:24 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

The FTC requested more merger documents on October 15, 2026. Sanara MedTech stock faces a 30-day wait and a year-end 2026 closing target.

Merger timing and operating figures

The Federal Trade Commission issued its second request on October 15, 2026.
Second-quarter 2026 revenue reached USD 28.14 million against USD 28.95 million expected.
The merger carries a year-end 2026 closing target, subject to regulatory approval.

SMTI, US79957L1008, Illustration mit AI erstellt.

Sanara MedTech (ISIN US79957L1008) faces a 30-day Hart-Scott-Rodino waiting period after the Federal Trade Commission requested additional merger information on October 15, 2026, according to StockTitan. The request delays the regulatory timetable for MiMedx Group's planned acquisition of Sanara.

FTC review changes the timetable

The second request extends the waiting period until 30 days after Sanara and MiMedx substantially comply, unless the parties extend it or the FTC ends it earlier. Completion also depends on other closing conditions, as the SEC filing shows.

The deal had carried a year-end 2026 closing target. TokenPost reported that the transaction values the consideration at USD 35.00 per Sanara share and includes USD 33.00 in cash plus 0.4735 MiMedx shares.

What does the deal mean for results?

Sanara's latest reported quarter provides a separate operating benchmark. For the second quarter of 2026, revenue was USD 28.14 million, below the USD 28.95 million consensus estimate, while adjusted loss per share was USD 0.05 against an expected USD 0.02 loss, according to MarketBeat. The revenue shortfall was USD 0.81 million, making execution a counterweight to the merger catalyst.

Three milestones define the path

On August 11, 2026, Sanara reported second-quarter revenue of USD 28.14 million, according to MarketBeat. On September 30, 2026, shareholders approved the merger with 6,372,989 votes in favor, according to the SEC filing. On October 15, 2026, the FTC issued the second request, extending the review period.

Next milestone is merger closing

The next stated transaction milestone is the year-end 2026 closing target, subject to regulatory approval and the remaining merger conditions. The extended review means the timing now depends on the parties' response to the FTC request and the date of substantial compliance.

Sanara keeps a regulatory focus

Sanara MedTech is listed on the Nasdaq Capital Market under SMTI and develops wound-care and surgical products. Its latest quarterly revenue comparison combines an operating miss with a transaction whose final timetable remains tied to antitrust review.